Physician profile
Anu Kurl
NPI 1003261967
$4,056.90
in general payments reported to CMS, 2019-2025
26 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $20.90 · 2023: $1,343 · 2024: $1,526 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,895 · Education: $19.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,894.60 |
| Education | $19.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $723.20 | 2023-2025 | |
| Amgen INC. | $532.81 | 2022-2025 | Tavneos, Enbrel, Otezla |
| Novartis Pharmaceuticals Corporation | $465.29 | 2023-2025 | |
| Ucb, INC. | $375.64 | 2023-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals Lp | $302.72 | 2023-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $277.29 | 2023-2025 | Benlysta, Nucala |
| Janssen Biotech, INC. | $223.04 | 2023-2025 | Tremfya |
| Mallinckrodt Hospital Products INC. | $178.01 | 2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.20 | 2023-2025 | Ofev, Cyltezo |
| Viiv Healthcare Company | $121.71 | 2021 | |
| Octapharma USA, INC. | $110.55 | 2023-2025 | Octagam Immune Globulin (Human), Panzyga |
| Sandoz INC. | $106.15 | 2023-2024 | Hyrimoz |
| E.R. Squibb & Sons, L.L.C. | $80.00 | 2024-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $76.61 | 2023-2024 | Lupkynis |
| Genzyme Corporation | $58.80 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $48.69 | 2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $42.72 | 2025 | Tremfya |
| Fresenius Kabi USA, LLC | $37.23 | 2025 | Tyenne |
| Actelion Pharmaceuticals US, INC. | $35.72 | 2023-2024 | Opsumit, Uptravi |
| Ani Pharmaceuticals, INC. | $26.96 | 2024 | Sovuna |
| Alexion Pharmaceuticals, INC. | $20.40 | 2024 | Strensiq |
| Sobi, INC | $17.95 | 2023 | |
| Organon LLC | $17.15 | 2024 | |
| Lilly USA, LLC | $15.68 | 2025 | Taltz, Zepbound |
| Kiniksa Pharmaceuticals International, Plc | $14.74 | 2024 | Arcalyst |
| Pfizer INC. | $14.64 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anu Kurl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.